{"filings":[{"id":2310796,"accession_number":"0001129928-26-000053","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-08-18T13:03:30+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics aligns with FDA on pivotal Part B expansion for REO 033 colorectal cancer study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA written feedback supports potential pivotal Part B expansion of REO 033 in 2L RAS-mutant MSS colorectal cancer.","Alignment on accelerated approval based on objective response rate; progression-free survival supports full approval.","Company to skip scheduled Type D meeting; will pursue End-of-Phase meeting for final registration program agreement.","Part B start-up activities to begin after positive interim Part A data; prior REO 022 data showed improved ORR, PFS, OS.","Pelareorep combination has FDA Fast Track designation in this patient population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-18","daily_digest_url":"/daily/2026-08-18","daily_digest_rank":6},{"id":1858116,"accession_number":"0001129928-26-000047","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-07-24T20:40:18+00:00","items":["3.01","9.01"],"status":"ready","headline":"Oncolytics Biotech receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 20, 2026, for non-compliance with $1.00 minimum bid price rule.","Common stock closed below $1.00 for 30 consecutive business days; ticker ONCY remains listed.","180-day compliance period ends January 19, 2027; must close at $1.00+ for 10 consecutive days.","If not cured, may qualify for additional 180-day period if other listing standards are met.","Company will monitor bid price and assess options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1731156,"accession_number":"0001129928-26-000045","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-07-20T13:03:03+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics Biotech receives FDA Fast Track for pelareorep in second-line anal cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track for pelareorep + checkpoint inhibitor in inoperable/metastatic squamous cell anal carcinoma after prior therapy.","GOBLET study showed ORR ~30% (vs historical ~15%), median DOR ~15.5 months, 12-month OS 82% (vs 45.7%).","No FDA-approved therapies exist for patients progressing after first-line standard of care; estimated US market ~$1B annually.","Third Fast Track designation in GI cancers (after KRAS-mCRC Feb 2026 and pancreatic cancer 2022).","Company believes clear regulatory framework in place for pivotal study following April 2026 FDA meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1592916,"accession_number":"0001129928-26-000043","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-07-13T13:03:54+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics: FDA Type D meeting in Aug; half of REO 033 sites activated, >20 patients pre-identified","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company to hold Type D meeting with FDA in first half of August 2026 to discuss registrational design for REO 033 Part B.","Approximately half of planned clinical sites for REO 033 Part A activated by end of July; more than 20 patients pre-identified.","Initial tumor response update from Part A expected by year-end 2026; Part B enrollment could begin Q1 2027 subject to FDA feedback.","Pelareorep has Fast Track designation from FDA for RAS-mutant MSS metastatic colorectal cancer.","Global lead PI Dr. Sanjay Goel opened enrollment at Rutgers Cancer Institute; remaining sites to be activated by end of August."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1526716,"accession_number":"0001104659-26-081797","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-07-08T20:23:21+00:00","items":["4.01","9.01"],"status":"ready","headline":"Oncolytics Biotech disengages EY, engages Baker Tilly as auditor after restructuring","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee voted to disengage EY and engage Baker Tilly for fiscal 2026, subject to client acceptance.","EY's reports for 2024 and 2025 contained no adverse opinion but included a going-concern explanatory paragraph.","No disagreements or reportable events with EY during the fiscal years ended 2024 and 2025.","Company provided EY with a copy of the 8-K and requested a letter to the SEC regarding the statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1066916,"accession_number":"0001129928-26-000041","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-06-16T13:05:18+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics secures new U.S. patent for pelareorep manufacturing through 2044; method-of-use app to 2046","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO issued patent covering pelareorep manufacturing process, expected protection into 2044.","Previously filed method-of-use patent application under review, if issued would protect into 2046.","Company plans additional patent filings in 2026 to expand IP across therapeutic applications and combinations.","CEO states patent supports commercial-scale production and long-term value of pelareorep."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":788516,"accession_number":"0001129928-26-000039","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-06-02T13:02:48+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Oncolytics appoints Steve Glover to board, promotes John McAdory to COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Glover appointed to board effective June 1, 2026; he chaired Ambrx during its $2B J&J acquisition.","John McAdory promoted to COO effective June 1, 2026; previously EVP Strategy & Operations since Jan 2026.","McAdory will oversee clinical ops, preclinical R&D, strategic partnerships, and business development.","Glover receives an option to purchase 96,000 shares vesting over three years; McAdory receives no extra compensation.","Glover brings 35+ years biopharma experience; also chairs ZyVersa Therapeutics and sits on PDS Biotech board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":760476,"accession_number":"0001129928-26-000037","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-06-01T13:06:14+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial data in solid tumor model shows greater anti-tumor activity with pelareorep+RAS inhibitor vs either alone.","Company planning additional studies in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models.","Evaluating combinations with KRAS G12C inhibitors, pan-RAS inhibitors, and next-generation RAS-targeted agents.","Full dataset expected to be presented in fall/winter 2026.","CEO states belief that pelareorep may serve as immune-priming backbone for next-generation targeted therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":592276,"accession_number":"0001129928-26-000035","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-05-22T13:03:22+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics posts translational data from GOBLET/AWARE-1 at ASCO 2026 supporting pelareorep immune activation","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Data from GOBLET (advanced pancreatic cancer) and AWARE-1 (early-stage breast cancer) to be presented at ASCO 2026 May 29-June 2.","In pancreatic cancer, expansion of pre-existing TIL clones correlated with tumor volume reduction; mutant KRAS-specific T-cell clones expanded.","In breast cancer, increased antiviral/immune gene expression, CXCL13 induction, and tertiary lymphoid structure formation by imaging mass cytometry.","Abstract 'Influence of pelareorep on mutant KRAS-specific blood TIL clonal expansion' (No. 2664) presented May 30, 1:30-4:30 p.m. CT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91467,"accession_number":"0001129928-26-000028","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.","Objective response rate 33% with pelareorep+FOLFIRI+bevacizumab, tripling the 6-11% standard of care.","Company actively engaging FDA to support potential accelerated approval pathway in this indication.","REO 022 study continues enrollment in randomized Phase 2 for 2L RAS-mutant MSS mCRC.","Data highlight durable benefit in a difficult-to-treat colorectal cancer population with few options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91466,"accession_number":"0001129928-26-000026","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics secures FDA alignment on pivotal anal cancer study for pelareorep","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on a randomized controlled pivotal trial design for pelareorep in post-first-line metastatic SCAC, targeting accelerated and full approval.","Prior pelareorep+checkpoint data showed median duration of response 15.5 months vs 9.5 months SOC; 12-month survival 82% vs 45.7%.","No FDA-approved therapies exist for SCAC after first-line chemo/checkpoint; over 10,000 US patients affected annually.","Company will finalize protocol using FDA feedback; study enables multiple endpoint assessments for potential simultaneous approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91465,"accession_number":"0001129928-26-000024","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics schedules Type C FDA meeting for pelareorep single-arm study in anal cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA meeting set for April 16, 2026 to discuss single-arm pivotal study of pelareorep + checkpoint inhibitor in SCAC.","Proposed enrollment of 60-70 second-line+ patients with no approved therapy; primary endpoint ORR for full approval.","GOBLET Cohort 4 achieved ~30% ORR and median DOR of 17 months vs real-world 10-14% ORR and 9.5 months DOR.","SCAC is a rare cancer with ~54,000 annual global cases; anal cancer market projected to reach $2.3B by 2035."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91464,"accession_number":"0001104659-26-039935","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics Biotech enters ATM agreement for up to $75M common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Jefferies LLC allows sale of up to $75M in common stock at market prices.","Proceeds to fund clinical development of pelareorep, R&D, operating costs, and general corporate purposes.","Jefferies will receive a commission of 3.0% of gross proceeds; company also reimburses certain expenses.","Shares sold under shelf registration effective April 3, 2026; prospectus supplement filed April 6, 2026.","Company is not obligated to sell any shares; either party may terminate on ten trading days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91463,"accession_number":"0001104659-26-038272","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["1.01","3.03","5.03","5.02","8.01","9.01"],"status":"ready","headline":"Oncolytics Biotech completes redomestication to Nevada; adopts new equity plan and governance documents","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redomestication from Canada to Nevada completed; common stock continues trading on Nasdaq under ONCY.","New CUSIP 68237V 103 and ISIN US68237V1035 effective April 1, 2026.","Board adopted 2026 Incentive Award Plan with 6.5M initial shares plus annual evergreen increase up to 6% of outstanding.","New indemnification agreements executed with all executive officers and directors.","Risk factor update warns of reduced stockholder rights under Nevada law, including exclusive forum provisions and no cumulative voting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101557,"accession_number":"0001104659-26-032763","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Oncolytics completes continuance to BC; expects Nevada domestication by March 31","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First step completed March 17: continuance from Alberta to British Columbia under BCBCA.","Second step expected March 31: domestication to Nevada; shares continue on Nasdaq as ONCY.","New CUSIP 68237V103 and ISIN US68237V1035 effective April 1; no name change.","Shareholder rights modified per BCBCA and will change under Nevada law; approved Jan 15, 2026.","Outstanding common shares unchanged; no impact on trading symbol or exchange listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101556,"accession_number":"0001129928-26-000011","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pelareorep data at AACR: 62% ORR in pancreatic cancer; TLS formation in breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GOBLET cohort 1: 62% objective response rate in first-line mPDAC, more than double historical chemotherapy alone.","Patients with immune activation signature had median PFS 7.5 months vs 5.6 months for those without.","AWARE-1 breast cancer study: pelareorep drove tertiary lymphoid structure formation in select patients.","Pelareorep stimulated RAS-specific T-cell clones in gastrointestinal cancers, presented at a future meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101555,"accession_number":"0001129928-26-000009","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics launches Phase 2 REO 033 trial in 2L RAS-mutant MSS mCRC; preliminary data expected by end of 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Randomized Phase 2 study (REO 033) of pelareorep + bevacizumab + FOLFIRI vs bevacizumab + FOLFIRI in 30 patients per arm.","Primary endpoint is ORR; secondary endpoints include PFS, OS, safety, and biomarker analysis; first site expected this month.","Prior REO 022 study showed median OS 27 months and PFS 16.6 months, vs 11.2 and 5.7 months for standard of care.","Pelareorep combination recently granted FDA Fast Track Designation for this indication.","Lead investigator is Dr. Sanjay Goel (Rutgers Cancer Institute); preliminary data by year-end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101554,"accession_number":"0001129928-26-000006","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics prioritizes SCAC and CRC registration studies; GOBLET enrollment closed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Concluded enrollment in GOBLET gastrointestinal study; now focusing on registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC).","Plans to meet with FDA mid-April to align on single-arm SCAC registrational study; believes <100 subjects may be sufficient for approval.","GOBLET Cohort 5 (PDAC) enrollment stopped at ~20 patients per arm; data to inform future PDAC strategy.","Sufficient cash on hand to execute near-term milestones, avoiding immediate material dilution.","GOBLET data support platform approach in GI cancers; company will follow existing Cohort 5 patients for survival data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101553,"accession_number":"0001129928-26-000004","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics gets FDA Fast Track for pelareorep in 2L KRAS-mutant MSS mCRC; interim data expected YE 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track Designation for pelareorep + bevacizumab + FOLFIRI in second-line KRAS-mutant MSS metastatic colorectal cancer.","Clinical data showed 33% ORR (vs ~10% SOC), 16.6-month PFS (vs 5.7 mo SOC), 27-month OS (vs 11.2 mo SOC).","Company plans controlled study with first site activated March 2026; interim data expected by end of 2026.","Estimated addressable market $3-5 billion annually for this difficult-to-treat population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101552,"accession_number":"0001104659-26-004103","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Oncolytics shareholders OK continuance to BC and domestication to Nevada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Continuance from Alberta to British Columbia approved: 85.21% in favor.","Domestication from British Columbia to Nevada approved: 86.98% in favor.","2026 Incentive Award Plan approved (76.77% in favor), conditional on completion of continuance and domestication.","Company expects to complete continuance and domestication by end of Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101551,"accession_number":"0001104659-26-003815","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics appoints EVP John McAdory and VP Biostatistics Yujun Wu, grants inducement awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John McAdory named EVP Strategy & Operations; previously VP Clinical Ops at CG Oncology (Nasdaq: CGON).","Yujun Wu named VP Head of Biostatistics; previously Head of Biostatistics at Morphic Therapeutic.","Inducement awards: McAdory 500k options + 300k RSUs; Wu 300k options; exercise price $0.97.","Appointments enhance execution for late-stage pancreatic, colorectal, and anal cancer trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101550,"accession_number":"0001104659-26-002863","cik":1129928,"company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncolytics: GOBLET Cohort 4 third-line anal cancer ORR 29%; median DOR ~17 months; files new patent application","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GOBLET Cohort 4: 4/14 evaluable third-line anal cancer patients responded (ORR 29%), 2 CRs, 2 PRs; median DOR ~17 months vs historical ~10%.","Second-line anal cancer: pelareorep + atezolizumab achieved 30% ORR (vs 13.8% standard of care), median DOR 15.5 months (vs 9.5 months).","Company planning Type C meeting with FDA in Q1 2026 to discuss accelerated approval pathway for third-line anal cancer.","Filed Track 1 patent application for pelareorep manufacturing; expects final USPTO action in Q3 2026; claims could extend to 2044.","Additional patent applications planned for manufacturing and method-of-use to potentially extend coverage beyond 2044."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":127130000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}